Progress and application of adipose-derived stem cells in the treatment of diabetes and its complications
Authors:
Open Access
- 2 January 2024
- journal article
- review article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 15 (1) , 1-32
Abstract
Diabetes mellitus (DM) is a serious chronic metabolic disease that can lead to many serious complications, such as cardiovascular disease, retinopathy, neuropathy, and kidney disease. Once diagnosed with diabetes, patients need to take oral hypoglycemic drugs or use insulin to control blood sugar and slow down the progression of the disease. This has a significant impact on the daily life of patients, requiring constant monitoring of the side effects of medication. It also imposes a heavy financial burden on individuals, their families, and even society as a whole. Adipose-derived stem cells (ADSCs) have recently become an emerging therapeutic modality for DM and its complications. ADSCs can improve insulin sensitivity and enhance insulin secretion through various pathways, thereby alleviating diabetes and its complications. Additionally, ADSCs can promote tissue regeneration, inhibit inflammatory reactions, and reduce tissue damage and cell apoptosis. The potential mechanisms of ADSC therapy for DM and its complications are numerous, and its extensive regenerative and differentiation ability, as well as its role in regulating the immune system and metabolic function, make it a powerful tool in the treatment of DM. Although this technology is still in the early stages, many studies have already proven its safety and effectiveness, providing new treatment options for patients with DM or its complications. Although based on current research, ADSCs have achieved some results in animal experiments and clinical trials for the treatment of DM, further clinical trials are still needed before they can be applied in a clinical setting.Keywords
Funding Information
- National Natural Science Foundation of China (82170336, 82270286, 82000227)
- Key R&D Program of China (2022YFC2402804)
- Key Science and Technology Program of Shaanxi Province (2023-ZDLSF-39)
This publication has 184 references indexed in Scilit:
- Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trialBMC Medicine, 2013
- Pericytes Derived from Adipose-Derived Stem Cells Protect against Retinal VasculopathyPLOS ONE, 2013
- Concurrent exposure to a dectin-1 agonist suppresses the Th2 response to epicutaneously introduced antigen in miceJournal of Biomedical Science, 2013
- Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in miceJournal of Clinical Investigation, 2012
- Concise Review: Mesenchymal Stem Cell Treatment of the Complications of Diabetes MellitusStem Cells, 2011
- Efficacy of Autologous Bone Marrow–Derived Stem Cell Transplantation in Patients With Type 2 Diabetes MellitusStem Cells and Development, 2009
- Treatment of Type 1 Diabetes With Adipose Tissue–Derived Stem Cells Expressing Pancreatic Duodenal Homeobox 1Stem Cells and Development, 2009
- miR-375 maintains normal pancreatic α- and β-cell massProceedings of the National Academy of Sciences, 2009
- Identification of an aberrant cell line among human adipose tissue-derived stem cell isolatesDifferentiation, 2009
- Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based TherapiesTissue Engineering, 2001